Eighty-nine HIV-1-infected antiretroviral-naive patients with < 100 CD4 cells per cubic millimeter were randomly assigned in a 1:1:1 ratio to efavirenz ( n = 29 ) , atazanavir/ritonavir ( n = 30 ) , or lopinavir/ritonavir ( n = 30 ) combined with tenofovir plus emtricitabine .